Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect
Telitacicept is effective in inducing MSE rapidly and offers a steroid-sparing effect, making it a promising alternative to traditional NSISTs with fewer side effects in MG patients.
Authors
- Qiaoyi Zhang
- Bingbing Wan
- Shengli Pan (ORCID: https://orcid.org/0000-0002-1904-6557)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3474-422X)
- Li Jia (ORCID: https://orcid.org/0000-0002-1979-5128)
- Yuan Zhang (ORCID: https://orcid.org/0009-0003-5998-1544)
- Shuya Yang
- Xu Zhang (ORCID: https://orcid.org/0009-0004-4086-9541)
- Zheyu Fang
- Xi Long Qu
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-24
- DOI
- https://doi.org/10.3389/fimmu.2025.1549034
- Citations
- 4
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 5.56